Cite
HARVARD Citation
Fisher, A. et al. (2023). Monitoring a Mandatory Nonmedical Switching Policy from Originator to Biosimilar Infliximab in Patients with Inflammatory Bowel Diseases: A Population-Based Cohort Study. Gastroenterology research and practice. p. . [Online].